Helix OpCo, LLC

Veracyte is continuing to aggressively build its cancer diagnostics business with an agreement to acquire HalioDx for €147m ($180m) in cash and up to €113m ($138m) in stock, the companies announced o

Device Transactions The device industry pulled in $1.5 billion in financing during the second quarter of 2016, a 15% drop from Q1's $1.8 billion. Once again, debt offerings played a big role, represen

2015 was a truly remarkable year for early-stage venture capital investment in the life science sector. The total amount of money raised in A rounds by life science companies (biopharma, pharma, medte

Device Transactions Device financing during 2015's third quarter reached $1.4 billion, a 22% dip from Q2's $1.8 billion total. ( See Exhibit 1. ) Late-stage venture capital rounds represented most of